​

Nurix Therapeutics (NRIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

NRIX Stock Forecast

Nurix Therapeutics (NRIX) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $31.22, with a high of $36.00 and a low of $28.00. This represents a 95.74% increase from the last price of $15.95.

$10 $16 $22 $28 $34 $40 High: $36 Avg: $31.22 Low: $28 Last Closed Price: $15.95

NRIX Stock Rating

Nurix Therapeutics stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 17 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 17 Strong Sell Sell Hold Buy Strong Buy

NRIX Price Target Upside V Benchmarks

TypeNameUpside
StockNurix Therapeutics95.74%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-419
Avg Price Target-$33.00$28.32
Last Closing Price$15.95$15.95$15.95
Upside/Downside-106.90%77.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26512---17
Feb, 26512---17
Jan, 264121--17
Dec, 254121--17
Nov, 256112--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 29, 2026Stifel Nicolaus$35.00$18.5688.58%119.44%
Jan 29, 2026Derek ArchilaWells Fargo$29.00$17.8762.28%81.82%
Jan 29, 2026H.C. Wainwright$32.00$17.8779.07%100.63%
Jan 08, 2026Morgan Stanley$36.00$18.4994.70%125.71%
Dec 10, 2025Robert BurnsH.C. Wainwright$31.00$19.5558.57%94.36%
Dec 09, 2025BTIG$30.00$21.4739.73%88.09%
Nov 24, 2025Truist Financial$30.00$17.1874.62%88.09%
Oct 28, 2025H.C. Wainwright$28.00$11.93134.70%75.55%
Oct 23, 2025BTIG$27.00$10.63154.00%69.28%
Oct 23, 2025Wells Fargo$21.00$10.47100.57%31.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 29, 2026Wells FargoOverweightOverweighthold
Jan 29, 2026Piper SandlerOverweightOverweighthold
Jan 29, 2026H.C. WainwrightBuyBuyhold
Jan 08, 2026Morgan StanleyEqual-WeightOverweightupgrade
Dec 10, 2025AldenBuyBuyhold
Dec 10, 2025H.C. WainwrightBuyBuyhold
Dec 09, 2025BTIGBuyBuyhold
Dec 08, 2025UBSBuyBuyhold
Oct 22, 2025RBC CapitalOutperformOutperformhold
Oct 20, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-2.73$-3.71$-2.65$-2.88$-3.05----
Avg Forecast$-2.54$0.59$-2.34$-2.81$-3.14$-3.37$-3.44$-2.45$-0.03
High Forecast$-1.81$1.55$-1.49$-2.61$-2.21$-1.82$-1.77$-1.51$-0.02
Low Forecast$-3.40$-0.38$-2.94$-3.04$-3.78$-4.53$-4.71$-4.76$-0.07
Surprise %7.48%-728.81%13.25%2.49%-2.87%----

Revenue Forecast

$0 $190M $380M $570M $760M $950M Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$29.75M$38.63M$76.99M$54.55M$83.98M----
Avg Forecast$35.21M$47.31M$94.04M$54.58M$57.44M$71.12M$100.48M$245.89M$536.49M
High Forecast$44.28M$56.78M$140.13M$64.72M$68.99M$147.28M$104.54M$424.06M$925.25M
Low Forecast$27.43M$37.85M$68.35M$41.35M$47.20M$44.47M$96.42M$172.97M$377.40M
Surprise %-15.50%-18.36%-18.14%-0.05%46.22%----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Nov 21 Nov 22 Nov 23 Nov 24 Nov 25 Nov 26 Nov 27 Nov 28 Nov 29
Nov 21Nov 22Nov 23Nov 24Nov 25Nov 26Nov 27Nov 28Nov 29
Reported$-117.19M$-180.36M$-143.95M$-193.57M$-264.46M----
Avg Forecast$-98.03M$-226.20M$-143.95M$-193.57M$-200.83M$-291.81M$-314.78M$-164.44M$-2.30M
High Forecast$-78.43M$-180.96M$-115.16M$-175.17M$-148.02M$-121.87M$-118.75M$-101.05M$-1.41M
Low Forecast$-117.64M$-271.43M$-172.74M$-204.03M$-253.65M$-303.86M$-316.43M$-319.36M$-4.47M
Surprise %19.55%-20.26%--31.68%----

NRIX Forecast FAQ

Is Nurix Therapeutics stock a buy?

Nurix Therapeutics stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Nurix Therapeutics is a favorable investment for most analysts.

What is Nurix Therapeutics's price target?

Nurix Therapeutics's price target, set by 17 Wall Street analysts, averages $31.22 over the next 12 months. The price target range spans from $28 at the low end to $36 at the high end, suggesting a potential 95.74% change from the previous closing price of $15.95.

How does Nurix Therapeutics stock forecast compare to its benchmarks?

Nurix Therapeutics's stock forecast shows a 95.74% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Nurix Therapeutics over the past three months?

  • March 2026: 29.41% Strong Buy, 70.59% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 29.41% Strong Buy, 70.59% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 23.53% Strong Buy, 70.59% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.

What is Nurix Therapeutics’s EPS forecast?

Nurix Therapeutics's average annual EPS forecast for its fiscal year ending in November 2026 is $-3.37, marking a 10.49% increase from the reported $-3.05 in 2025. Estimates for the following years are $-3.44 in 2027, $-2.45 in 2028, and $-0.03 in 2029.

What is Nurix Therapeutics’s revenue forecast?

Nurix Therapeutics's average annual revenue forecast for its fiscal year ending in November 2026 is $71.12M, reflecting a -15.31% decrease from the reported $83.98M in 2025. The forecast for 2027 is $100.48M, followed by $245.89M for 2028, and $536.49M for 2029.

What is Nurix Therapeutics’s net income forecast?

Nurix Therapeutics's net income forecast for the fiscal year ending in November 2026 stands at $-292M, representing an 10.34% increase from the reported $-264M in 2025. Projections indicate $-315M in 2027, $-164M in 2028, and $-2.301M in 2029.